Editorial Standards
Our approach to sourcing, accuracy, and the kinds of claims we do (and don't) make.
Sourcing
Articles on Chubby Smoke Learn rely on three categories of sources:
- Primary sources for legal claims — federal statutes (cited by public law number and section), regulatory documents (USDA, FDA, DEA), state laws and rules (cited by statute or administrative code), and federal court decisions. Where we describe what a law does, we work from the text of the law itself.
- Peer-reviewed research for scientific claims — published studies in pharmacology, biochemistry, and clinical research. Where claims are well-established (basic cannabinoid pharmacology, for example), we treat them as settled. Where research is preliminary, mixed, or contested, we say so.
- Authoritative analysis for context — Congressional Research Service reports, white papers from regulatory agencies, established trade publications. We use these to provide context but don't treat them as definitive on questions where the underlying sources disagree.
What we avoid
We don't cite blog posts, forum discussions, or other secondary sources as evidence for factual claims. Marketing materials from hemp producers are not sources for what cannabis does or doesn't do in the body. We don't link to social media as a source for scientific or legal claims.
Accuracy and corrections
Hemp law and cannabinoid science both move quickly. When we publish an article, we date it. When we revise an article based on new developments or to correct an error, we note the revision. Major corrections that change the meaning of an article are flagged at the top of the page.
If you spot something inaccurate, please tell us. We aim to respond to correction requests within a few business days.
Uncertainty
Where the law is in flux, we say so. Where the research base is thin, we say so. Where reasonable people disagree about interpretation, we present the disagreement rather than picking a side. Readers should be able to tell from our articles which claims are well-established and which are contested.
This is especially important in hemp policy. As of this writing, the November 12, 2026 effective date of Public Law 119-37 is firm, but multiple bills to delay, repeal, or replace it have been introduced. We try to be precise about what is settled, what is enacted but pending, and what is genuinely uncertain.
What we don't do
- Medical advice. We describe how cannabinoids work in the body. We do not tell readers what is safe for them personally, what doses they should use, or whether a given product is right for their situation.
- Legal advice. We describe what laws say. We do not tell readers whether a given action is legal in their specific situation, what to do if they're facing legal consequences, or how to interpret ambiguous statutes for their personal circumstances.
- Product recommendations. We don't rank, review, or recommend specific hemp products. Where articles describe product categories, they do so in general terms.
- Drug-test workarounds or detection-evasion guidance. Articles about drug testing explain how tests work and what they detect. They don't advise on circumventing them.
FDA disclosure
Statements on this site about cannabinoids and their effects have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure, or prevent any disease.
Updates to these standards
We update this page when our editorial practices change. The current version was last reviewed in May 2026.